Chia-Ying Lai

Chia-Ying Lai

Auto-generated profile, based on publicly available information

Chia-Ying Lai

Department of Physical Medicine and Rehabilitation School of Medicine, College of Medicine, National Defense Medical University Taipei Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
CLChia-Ying Lai
Chia-Ying Lai
Chia-Huei LinChia-Huei Lin
Chia-Huei Lin
Ta-Chung ChaoTa-Chung Chao
Ta-Chung Chao
CLChueh-Ho Lin
Chueh-Ho Lin
CCCheng-Chiang Chang
Cheng-Chiang Chang
SCShang-Lin Chiang
Shang-Lin Chiang

19 January 2022 in Pain Medicine
Verified
Journal Article
Closed access
PDF file
CLChia-Ying Lai
Chia-Ying Lai
TLTsung-Ying Li
Tsung-Ying Li
King Hei Stanley LamKing Hei Stanley Lam
King Hei Stanley Lam
YCYu-Ching Chou
Yu-Ching Chou
Dueng-Yuan HuengDueng-Yuan Hueng
Dueng-Yuan Hueng
YWYung-Tsan Wu
Yung-Tsan Wu
Interest in perineural platelet-rich-plasma (PRP) injections for the treatment of carpal tunnel syndrome (CTS) has increased in recent years. However, evidence supporting the long-term effectiveness of PRP is lacking. Therefore, the aim of our cross-sectional cohort study was to investigate the long-term results of PRP injections for CTS. Eighty-one patients diagnosed with CTS of any grade who received a single PRP injection at least 2 years prior were enrolled. Through structured telephone interviews, all patients were asked of their post-injection outcomes compared to their pre-injection condition. Symptom relief ≥50%, compared to the pre-injection condition, was considered an effective outcome. Binary logistic regression was applied to analyze each baseline variable as a regressor for determining the prognostic outcome factors. In total, 70% of patients reported positive outcomes ≥2 years post-injection. Shorter duration of symptoms before treatment (odds ratio: 0.991; 95% confidence interval [CI] 0.983–0.999; P = .023) and lower electrodiagnostic severity of CTS were the main prognostic factors for an effective outcome (mild grade vs severe grade, odds ratio: 17.652; 95% CI 1.43–221.1; P = .025). Although there was a trend toward positive outcomes at longer follow-up durations (2–3 years vs 3–4 years vs 4–5 years), the difference was not statistically significant. A single perineural PRP injection has a long-term analgesic effect on CTS, especially in mild-to-moderate cases.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YWYung-Tsan Wu
Yung-Tsan Wu
King Hei Stanley LamKing Hei Stanley Lam
King Hei Stanley Lam
CLChia-Ying Lai
Chia-Ying Lai
SCSi-Ru Chen
Si-Ru Chen
YSYu-Ping Shen
Yu-Ping Shen
CWChueh-Hung Wu
Chueh-Hung Wu
Nerve hydrodissection uses fluid injection under pressure to selectively separate nerves from areas of suspected entrapment; this procedure is increasingly viewed as potentially useful in treating carpal tunnel syndrome (CTS). The usage of normal saline (NS), 5% dextrose water (D5W), platelet‐rich plasma (PRP), and hyaluronic acid (HA) as primary injectates for hydrodissection without an anesthetic can limit anesthetic‐related toxicity and preserve the motor functions of the median nerve. Here, we describe a novel motor‐sparing neural injection and compare the effect of these four injectates for severe CTS. We retrospectively reviewed the outcomes of 61 severe CTS cases after a single neural injection with NS, D5W, PRP, or HA. Outcomes were evaluated on the 1st and 6th months postinjection, including the Boston Carpal Tunnel Questionnaire (BCTQ) scores and the nerve cross‐sectional area (CSA). The results revealed that PRP, D5W, and HA were more efficient than NS at all measured time points (p < 0.05), except for CSA at the 1st month between the NS and D5W groups. Single‐injections of PRP and D5W seemed more effective than that of HA within 6 months postinjection for symptom and functional improvement (6th‐month BCTQ‐symptom, D5W vs. HA, p = 0.047; 1st‐month BCTQ‐symptom, PRP vs. HA, p = 0.018; 1st‐ and 6th‐month BCTQ‐function, D5W vs. HA, p = 0.002 and 0.016, respectively; 1st‐month BCTQ‐function, PRP vs. HA, p < 0.001). For reducing CSA, PRP and HA seemed more effective than D5W (HA > PRP > D5W on the 1st month and HA vs. D5W, p = 0.001; PRP > HA > D5W on the 6th month and PRP vs. D5W, p = 0.012).

5 July 2024 in Life
Verified
Journal Article
Open access
PDF file
Ta-Chung ChaoTa-Chung Chao
Ta-Chung Chao
Chia-Huei LinChia-Huei Lin
Chia-Huei Lin
MLMeei-Shyuan Lee
Meei-Shyuan Lee
CCCheng-Chiang Chang
Cheng-Chiang Chang
CLChia-Ying Lai
Chia-Ying Lai
SCShang-Lin Chiang
Shang-Lin Chiang
Early rehabilitation has beneficial impacts on functional outcomes for patients with acute stroke. However, whether the addition of virtual reality (VR) training could further improve these patients’ muscle strength, functional recovery, and psychological health is unknown. A randomized controlled trial was conducted on 33 patients with first-time acute ischemic stroke. The patients were randomly assigned using a 1:1 randomization ratio to either the experimental group (EG) or the comparison group (CG). Both groups received early rehabilitation, and the EG received extra VR training during their stay in the hospital. Muscle strength, functional status, and psychological health were assessed before the intervention and at discharge. Generalized estimating equations were used to examine the intervention effects via the interaction of time and group. After adjusting for potential covariates, the EG showed a more significant decrease in depression at discharge than the CG (ß = 3.77, p = 0.011). There were no differences in muscle strength and functional recovery between groups after intervention. Adding VR training into early rehabilitation facilitates substantial positive effects on psychological health, specifically depression, but not muscle strength and functional recovery, compared to receiving early rehabilitation alone in patients with first-time acute stroke during their hospitalized period.


20 July 2025 in JMIR Preprints
Verified
Preprint
Open access
CLChia-Ying Lai
Chia-Ying Lai
Chia-Huei LinChia-Huei Lin
Chia-Huei Lin
WCWen-Yuan Chang
Wen-Yuan Chang
CSChieh-Yi Song
Chieh-Yi Song
CCCheng-Chiang Chang
Cheng-Chiang Chang
SCShang-Lin Chiang
Shang-Lin Chiang
BACKGROUND Telerehabilitation has emerged as a promising intervention, with evidence indicating potential benefits for physical function, symptoms, and quality of life (QOL) in individuals with long COVID. However, current research remains limited and shows inconsistent results, particularly regarding its effects on gait speed. OBJECTIVE To evaluate the efficacy of a 12-week mobile-based telerehabilitation exercise program on cardiorespiratory fitness (CRF), gait speed, symptom relief, sleep quality, and QOL in participants with long COVID. METHODS This randomized controlled trial was conducted at a rehabilitation outpatient clinic at a medical center in northern Taiwan. A total of 120 eligible participants aged 20–80 years with long COVID who attended the outpatient clinic were enrolled. Both the experimental group (EG, n =57) and comparison group (CG, n =63) received face-to-face physical activity promotion counseling delivered by a research nurse. In addition, the EG participated in a 12-week mobile-based, physical therapist-assisted telerehabilitation program that combined aerobic and resistance training. Primary outcomes included CRF, gait speed, and symptoms of long COVID were assessed in person by the other research nurse who was a blinded assessor. Secondary outcomes included body composition, sleep quality (Pittsburgh Sleep Quality Index), and QOL (World Health Organization Quality of Life-BREF), were assessed via a combination of in-person measurements and self-administered questionnaires. RESULTS Compared to the CG, the EG demonstrated significantly greater improvements in CRF (peak VO₂, β = 2.12, p = 0.01) and gait speed (β = 0.07, p < 0.001), along with a lower risk of symptoms such as fatigue (odds ratio = 0.20, p < 0.001). At 12 weeks, the EG also showed increased lean mass (β = 1.32, p < 0.001), improved sleep quality (β = –0.58, p = 0.034), and enhanced physical (β = 0.97, p = 0.0033) and social (β = 0.77, p = 0.049) domains of QOL compared to the CG. CONCLUSIONS A 12-week mobile-based telerehabilitation exercise program yielded beneficial effects on CRF, gait speed, body composition, symptoms of long COVID, sleep quality, and QOL in participants with long COVID. These findings support the feasibility and effectiveness of telerehabilitation as an approach to promote recovery and well-being in this population. CLINICALTRIAL This trial was prospectively registered at ClinicalTrials.gov (Identifier: NCT05922865).